CCNA2 and prostate adenocarcinoma: Furthermore, immunohistochemistry experiments validated the upregulation of CCNA2 expression in PRAD and its correlation with patient prognosis.<h4>Conclusion</h4>Our findings offer new insights into monocyte heterogeneity and its role in PRAD.